Skip to Content

Cronos Group Inc CRON

Morningstar Rating
$2.87 +0.02 (0.70%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Cronos Earnings: Surprising Progress on Narrowing Losses, but Small Size Still a Challenge

No-moat Cronos reported decent first-quarter results, with net revenue of $25 million, up 6% sequentially, and an adjusted EBITDA loss of about $11 million. We were surprised by the progress on narrowing its loss, which was half that of the preceding quarter. Impressively, this improvement came through a combination of higher gross profit (reflecting some operational improvement) and lower overhead expenses. The results put the company on track to beat our preprint full-year estimates for revenue of $98 million and an adjusted EBITDA loss of $55 million. We expect to tick up our fair value estimates of $2 and CAD 2.80 by mid to high-single-digit percentages, expecting better near-term performance.

Price vs Fair Value

CRON is trading at a 493% premium.
Price
$2.85
Fair Value
$8.00
Uncertainty
Very High
1-Star Price
$7.30
5-Star Price
$7.00
Economic Moat
Qktp
Capital Allocation
Qsgxzxklp

Bulls Say, Bears Say

Bulls

Altria Group’s investment of $1.8 billion provides Cronos with capital and a strategic partner with significant product development, branding, and regulatory experience. If successful, Altria Group may increase its ownership of Cronos or potentially acquire it.

Bears

Cronos' small size adds difficulty to reaching profitability, as it struggles to leverage overhead expenses.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRON is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.85
Day Range
$2.862.93
52-Week Range
$1.643.00
Bid/Ask
$2.87 / $2.88
Market Cap
$1.09 Bil
Volume/Avg
697,779 / 3.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
12.45
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
356

Competitors

Valuation

Metric
CRON
TLRY
ACB
Price/Earnings (Normalized)
Price/Book Value
0.990.460.83
Price/Sales
12.451.901.21
Price/Cash Flow
Price/Earnings
CRON
TLRY
ACB

Financial Strength

Metric
CRON
TLRY
ACB
Quick Ratio
21.680.961.79
Current Ratio
22.541.923.79
Interest Coverage
−4.39
Quick Ratio
CRON
TLRY
ACB

Profitability

Metric
CRON
TLRY
ACB
Return on Assets (Normalized)
−0.53%−1.42%
Return on Equity (Normalized)
−0.55%−1.82%
Return on Invested Capital (Normalized)
−4.90%−0.92%
Return on Assets
CRON
TLRY
ACB
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AHdcvxrqpcjNdv$76.9 Bil
MKKGY
Merck KGaA ADRKnchdlscjYgxvskm$72.0 Bil
HLN
Haleon PLC ADRTqzdgwpcVbtw$37.5 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRCzdnmfzkZnzt$17.9 Bil
VTRS
Viatris IncZmtrcjzvbCby$13.4 Bil
RDY
Dr Reddy's Laboratories Ltd ADRLbxlmmrsbDwryp$11.7 Bil
CTLT
Catalent IncGgtmvbhyQznrdk$10.1 Bil
PRGO
Perrigo Co PLCYcrgyfnZnmj$4.2 Bil
CURLF
Curaleaf Holdings IncCyyxzjqlJyc$4.0 Bil
PBH
Prestige Consumer Healthcare IncWvpzmbrHtxcf$3.5 Bil

Sponsor Center